期刊
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
卷 1875, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.bbcan.2020.188446
关键词
Angiogenesis; Anti-angiogenic therapy; Endothelial cells; Endothelial cell metabolism; Gynecological cancer; Non-tip cells; Tip cells; Tumor microenvironment; Vascular disrupting agents
资金
- Landelijke Stichting voor Blinden en Slechtzienden through UitZicht [2018-26, 2017-29, 2015-19]
- Algemene Nederlandse Vereniging ter Voorkoming van Blindheid through UitZicht [2018-26, 2017-29, 2015-19]
- Stichting Blinden-Penning through UitZicht [2018-26, 2017-29, 2015-19]
- Stichting Oogfonds Nederland through UitZicht [2018-26, 2017-29, 2015-19]
- MaculaFonds through UitZicht [2018-26, 2017-29, 2015-19]
- Stichting tot Verbetering van het Lot der Blinden
- Rotterdamse Stichting Blindenbelangen [B20140049]
- Stichting voor Ooglijders
- Stichting Blindenhulp
- Slovenian Research Agency (ARRS) [J3-2526]
A better understanding of angiogenesis and the tumor microenvironment in gynecological cancers is urgently needed to develop more effective anti-angiogenic therapies. The current survival benefits of anti-angiogenic agents in patients with gynecological cancer, such as bevacizumab, are modest, highlighting the need for research into more effective treatment methods.
Angiogenesis is required in cancer, including gynecological cancers, for the growth of primary tumors and secondary metastases. Development of anti-angiogenesis therapy in gynecological cancers and improvement of its efficacy have been a major focus of fundamental and clinical research. However, survival benefits of current anti-angiogenic agents, such as bevacizumab, in patients with gynecological cancer, are modest. Therefore, a better understanding of angiogenesis and the tumor microenvironment in gynecological cancers is urgently needed to develop more effective anti-angiogenic therapies, either or not in combination with other therapeutic approaches. We describe the molecular aspects of (tumor) blood vessel formation and the tumor microenvironment and provide an extensive clinical overview of current anti-angiogenic therapies for gynecological cancers. We discuss the different phenotypes of angiogenic endothelial cells as potential therapeutic targets, strategies aimed at intervention in their metabolism, and approaches targeting their (inflammatory) tumor microenvironment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据